Medpace Holdings, Inc. (NASDAQ:MEDP) Stock Holdings Lifted by Kestra Investment Management LLC

Kestra Investment Management LLC raised its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 58.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,105 shares of the company’s stock after purchasing an additional 407 shares during the period. Kestra Investment Management LLC’s holdings in Medpace were worth $367,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. R Squared Ltd acquired a new position in Medpace in the fourth quarter worth approximately $30,000. Stone House Investment Management LLC bought a new stake in Medpace in the third quarter worth approximately $33,000. Ashton Thomas Securities LLC acquired a new position in shares of Medpace during the 3rd quarter worth $37,000. Capital Performance Advisors LLP bought a new position in shares of Medpace during the 3rd quarter valued at $46,000. Finally, True Wealth Design LLC lifted its stake in shares of Medpace by 16,800.0% in the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock valued at $56,000 after purchasing an additional 168 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

MEDP has been the topic of several analyst reports. Robert W. Baird increased their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. TD Cowen lowered their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Finally, Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Medpace currently has an average rating of “Hold” and an average price target of $381.44.

Medpace Stock Up 1.0 %

MEDP opened at $344.01 on Thursday. The stock’s 50 day moving average price is $343.28 and its two-hundred day moving average price is $347.47. The firm has a market capitalization of $10.48 billion, a P/E ratio of 27.24, a price-to-earnings-growth ratio of 3.76 and a beta of 1.36. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.